Navigation Links
InNexus Biotechnology Strengthens Patent Team With New Leadership
Date:9/9/2008

BRITISH COLUMBIA, Canada, Sept. 9 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX: IXS.V, OTC Bulletin Board: IXSBF, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, welcomes David Warden to its Board of Directors.

Mr. Warden was a founding partner of Yetter, Warden & Coleman, L.L.P. In his 23 years of practice, he has represented both plaintiffs and defendants in cases pertaining to antitrust, securities violations, trade secrets, patents, and other business and technology litigation.

"I am pleased to have David join our team as a director on our Board," said Jeff Morhet, Chairman and CEO. "His broad legal experience and, in particular, his expertise in patent law will prove valuable as we continue to expand and fortify our intellectual property position. I look forward to working with David as a valuable addition to our Board."

Mr. Warden is considered one of Houston's top Lawyers from H magazine and recognized as one of the Texas "Super Lawyers" in Texas Monthly magazine from 2003-2006. Warden has published many articles during his career, "Trade Secrets and Patents: Comparison and Contrasts in Royalty Determination," and "How to Quantify Trade Secrets Theft," are among them. He received his B.S. and his M.S. in Engineering from Purdue University and obtained his Juris Doctorate degree in 1981 from the University of Virginia.

InNexus has taken deliberate steps to enhance its intellectual property position. This latest addition follows a previous appointment of Gilbert Gabo, as the company's Vice President of Operations and Director of Legal Affairs. Mr. Gabo was a practicing patent attorney with the law firm of Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C. before joining the company and also brings a decade of operations experience from his work as a product engineer. He received his J.D. in 2001 from the University of Detroit Mercy Law School and his B.S. in Engineering in 1993 from the University of Michigan in Ann Arbor.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
6. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
7. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
8. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
9. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
10. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
11. Leading Biotechnology Company Grows with StayinFront CRM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 On Thursday, ... session at 5,817.69, down 0.07%; the Dow Jones Industrial ... the S&P 500 closed at 2,345.96, marginally dropping 0.11%. ... closed in green, 4 sectors finished in red, and ... Stock-Callers.com has initiated reports coverage on the following Biotechnology ...
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... ... ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event company in ... the world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category ... due to its new team building format, a way for teams to not only interact ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):